Skip to main content
Premium Trial:

Request an Annual Quote

New England Biolabs, CasZyme Collaborate to Identify, Commercialize CRISPR-Cas Nucleases

NEW YORK (GenomeWeb) – New England Biolabs and startup company CasZyme announced today that they have formed a multi-year collaboration to identify and commercialize CRISPR-Cas nucleases.

Under the terms of the agreement, the two companies will work to characterize new Cas nucleases using their expertise in enzymology, and NEB will then manufacture and commercially distribute the nucleases globally.

"The scientific founders of CasZyme are pioneers in CRISPR-Cas research, with a significant history of advancing our understanding of key enzymes involved in nucleic acid recognition in the context of bacterial immune systems," Ted Davis, NEB's executive director of applications and product development, said in a statement. "We are excited to undertake this joint endeavor that we believe will advance CRISPR-Cas science and enable new applications of Cas9 enzymes in vitro and in vivo."

CasZyme, which is based in Lithuania, is developing and characterizing new tools to support CRISPR-Cas research. One of its founders is Vilnius University Professor Virginijus Šikšnys, who demonstrated in 2012 that CRISPR-Cas9 can be used to engineer precise double-strand breaks in DNA.

The Scan

Study Links Genetic Risk for ADHD With Alzheimer's Disease

A higher polygenic risk score for attention-deficit/hyperactivity disorder is also linked to cognitive decline and Alzheimer's disease, a new study in Molecular Psychiatry finds.

Study Offers Insights Into Role of Structural Variants in Cancer

A new study in Nature using cell lines shows that structural variants can enable oncogene activation.

Computer Model Uses Genetics, Health Data to Predict Mental Disorders

A new model in JAMA Psychiatry finds combining genetic and health record data can predict a mental disorder diagnosis before one is made clinically.

Study Tracks Off-Target Gene Edits Linked to Epigenetic Features

Using machine learning, researchers characterize in BMC Genomics the potential off-target effects of 19 computed or experimentally determined epigenetic features during CRISPR-Cas9 editing.